The Epigenetics of Alzheimer’s Disease: Factors and Therapeutic Implications
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a well-known neurodegenerative disorder that imposes a great burden on the world. The mechanisms of AD are not yet fully understood. Current insight into the role of epigenetics in the mechanism of AD focuses on DNA methylation, remodeling of chromatin, histone modifications and non-coding RNA regulation. This review summarizes the current state of knowledge regarding the role of epigenetics in AD and the possibilities for epigenetically based therapeutics. The general conclusion is that epigenetic mechanisms play a variety of crucial roles in the development of AD, and there are a number of viable possibilities for treatments based on modulating these effects, but significant advances in knowledge and technology will be needed to move these treatments from the bench to the bedside.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Faghihi, M. A., Modarresi, F., Khalil, A. M., Wood, D. E., Sahagan, B. G., Morgan, T. E., Finch, C. E., St. Laurent III, G., Kenny, P. J., & Wahlestedt, C. (2008) · Nature Medicine · doi:10.1038/nm1784 · Cited by 1,416 · cited 1×
“Furthermore, the overexpression of Aβ and Aβ-42 in AD could increase BACE1 antisense transcript lncRNA levels, leading to amyloid protein aggregation (Faghihi et al., 2008).”
BackgroundTransvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167 · cited 1×
“A type of ncRNA called 51A has been found to regulate the SORL1 gene, which encodes a sorting receptor for the APP holoprotein (Rogaeva et al., 2007).”
BackgroundRegulation of histone acetylation during memory formation in the hippocampus
Levenson, J. M., O'Riordan, K. J., Brown, K. D., Trinh, M. A., Molfese, D. L., & Sweatt, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402229200 · Cited by 1,131
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 5×
“In general, only molecules less than 500 daltons, with fewer than 8 pairs of hydrogen bonds, can move through the BBB.”
MethodInfluentialAltered Histone Acetylation Is Associated with Age-Dependent Memory Impairment in Mice
Peleg, S., Sananbenesi, F., Zovoilis, A., Burkhardt, S., Bahari-Javan, S., Agis-Balboa, R. C., Cota, P., Wittnam, J. L., Gogol-Doering, A., Opitz, L., et al. (2010) · Science · doi:10.1126/science.1186088 · Cited by 951
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943 · cited 1×
“There is extensive evidence that SIRT1 reduction is involved in AD tau pathology, and tau acetylation of lysine 28 inhibits tau function via impaired tau-microtubule interactions, promoting tau aggregation (Cohen et al., 2011).”
BackgroundAn epigenetic blockade of cognitive functions in the neurodegenerating brain
Gräff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., et al. (2012) · Nature · doi:10.1038/nature10849 · Cited by 853
Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.197 · Cited by 727
The acetylation of tau inhibits its function and promotes pathological tau aggregation
Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724
Champagne, F., Diorio, J., Sharma, S., & Meaney, M. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221224598 · Cited by 707
Circular RNA (circRNA) in Alzheimer’s disease (AD)
Lukiw, W. J. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00307 · Cited by 636 · cited 6×
“In an in vitro preparation, MiR-16 was found to be an effective inhibitor of amyloid precursor protein (APP) and BACE1 expression, Aβ peptide production, and tau phosphorylation (Parsi et al., 2015). miRNA regulators have also been evaluated for use in treating AD.”
BackgroundInfluentialRocca, W. A., Petersen, R. C., Knopman, D. S., Hebert, L. E., Evans, D. A., Hall, K. S., Gao, S., Unverzagt, F. W., Langa, K. M., Larson, E. B., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.11.002 · Cited by 498
Ricobaraza, A., Cuadrado-Tejedor, M., Pérez-Mediavilla, A., Frechilla, D., Del Río, J., & García-Osta, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.229 · Cited by 423
Green, K. N., Steffan, J. S., Martinez-Coria, H., Sun, X., Schreiber, S. S., Thompson, L. M., & LaFerla, F. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3203-08.2008 · Cited by 404
Histone deacetylase 6 interacts with the microtubule‐associated protein tau
Ding, H., Dolan, P. J., & Johnson, G. V. W. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05564.x · Cited by 387
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
microRNA-34c is a novel target to treat dementias
Zovoilis, A., Agbemenyah, H. Y., Agis‐Balboa, R. C., Stilling, R. M., Edbauer, D., Rao, P., Farinelli, L., Delalle, I., Schmitt, A., Falkai, P., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.327 · Cited by 353
miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model
Lee, S., Chu, K., Jung, K., Kim, J. H., Huh, J., Yoon, H., Park, D., Lim, J., Kim, J., Jeon, D., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23588 · Cited by 326
Ricobaraza, A., Cuadrado‐Tejedor, M., Marco, S., Pérez‐Otaño, I., & García‐Osta, A. (2012) · Hippocampus · doi:10.1002/hipo.20883 · Cited by 239
An Essential Role for Histone Deacetylase 4 in Synaptic Plasticity and Memory Formation
Kim, M.-S., Akhtar, M. W., Adachi, M., Mahgoub, M., Bassel-Duby, R., Kavalali, E. T., Olson, E. N., & Monteggia, L. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2089-12.2012 · Cited by 235
Datta, M., Staszewski, O., Raschi, E., Frosch, M., Hagemeyer, N., Tay, T. L., Blank, T., Kreutzfeldt, M., Merkler, D., Ziegler-Waldkirch, S., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.02.016 · Cited by 206 · cited 2×
“Di Francesco et al. (2015) found that global DNA methylation in the peripheral blood mononuclear cells of LOAD patients was higher compared to healthy controls, and higher DNA methylation levels were associated with the presence of APOE ε4 allele (p = 0.0043) and APOE ε3 carriers (p = 0.05) in the…”
BackgroundResultInfluentialIn Vitro Reactivation of the FMR1 Gene Involved in Fragile X Syndrome
Chiurazzi, P., Pomponi, M. G., Willemsen, R., Oostra, B. A., & Neri, G. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.1.109 · Cited by 198
Smith, R. G., Hannon, E., De Jager, P. L., Chibnik, L., Lott, S. J., Condliffe, D., Smith, A. R., Haroutunian, V., Troakes, C., Al‐Sarraj, S., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.017 · Cited by 184
Pereira Diniz, L., Tortelli, V., Matias, I., Morgado, J., Bérgamo Araujo, A. P., Melo, H. M., Seixas da Silva, G. S., Alves-Leon, S. V., de Souza, J. M., Ferreira, S. T., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3351-16.2017 · Cited by 171 · cited 5×
“Among them, the ε4 isoform of apolipoprotein E (ApoE4) is well-known as the strongest genetic risk factor for LOAD (Lane-Donovan and Herz, 2017).”
BackgroundInfluentialApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease
Lane-Donovan, C., & Herz, J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.12.001 · Cited by 157 · cited 5×
“Among them, the ε4 isoform of apolipoprotein E (ApoE4) is well-known as the strongest genetic risk factor for LOAD (Lane-Donovan and Herz, 2017).”
BackgroundInfluentialMicroglia limit the expansion of β-amyloid plaques in a mouse model of Alzheimer’s disease
Zhao, R., Hu, W., Tsai, J., Li, W., & Gan, W.-B. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0188-6 · Cited by 151
Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain
Condliffe, D., Wong, A., Troakes, C., Proitsi, P., Patel, Y., Chouliaras, L., Fernandes, C., Cooper, J., Lovestone, S., Schalkwyk, L., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.002 · Cited by 131
Pogue, A. I., & Lukiw, W. J. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0572-3 · Cited by 105 · cited 1×
“These seven upregulated miRNAs are involved in the coordination of amyloid production and clearance (Pogue and Lukiw, 2018).”
BackgroundLong Noncoding RNA EBF3-AS Promotes Neuron Apoptosis in Alzheimer's Disease
Gu, C., Chen, C., Wu, R., Dong, T., Hu, X., Yao, Y., & Zhang, Y. (2018) · DNA and Cell Biology · doi:10.1089/dna.2017.4012 · Cited by 101
Aggregates of Small Nuclear Ribonucleic Acids ( snRNAs ) in Alzheimer's Disease
Hales, C. M., Dammer, E. B., Diner, I., Yi, H., Seyfried, N. T., Gearing, M., Glass, J. D., Montine, T. J., Levey, A. I., & Lah, J. J. (2014) · Brain Pathology · doi:10.1111/bpa.12133 · Cited by 89
Hales, C. M., Seyfried, N. T., Dammer, E. B., Duong, D., Yi, H., Gearing, M., Troncoso, J. C., Mufson, E. J., Thambisetty, M., Levey, A. I., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-15 · Cited by 58 · cited 1×
“Levels of members of the miR-29 family, including miR-29a, miR-29b, and miR29c, are decreased in the brains of patients with AD, and this is related to high BACE1 protein expression (Hebert et al., 2008).”
BackgroundExpression of BC1 Impairs Spatial Learning and Memory in Alzheimer’s Disease Via APP Translation
Zhang, T., Pang, P., Fang, Z., Guo, Y., Li, H., Li, X., Tian, T., Yang, X., Chen, W., Shu, S., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0820-z · Cited by 52
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Zhang, L., Silva, T. C., Young, J. I., Gomez, L., Schmidt, M. A., Hamilton-Nelson, K. L., Kunkle, B. W., Chen, X., Martin, E. R., & Wang, L. (2020) · Nature Communications · doi:10.1038/s41467-020-19791-w · Cited by 139
Editing the Epigenome to Tackle Brain Disorders
Liu, X. S., & Jaenisch, R. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.10.003 · Cited by 56
Self-citationNeuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease
Maggiore, A., Casale, A. M., Toscanelli, W., Cappucci, U., Rotili, D., Grieco, M., Gagné, J.-P., Poirier, G. G., d’Erme, M., & Piacentini, L. (2022) · Cells · doi:10.3390/cells11081284 · Cited by 40
Effect of C-phycocyanin on HDAC3 and miRNA-335 in Alzheimer’s disease
Li, Z., Gan, L., Yan, S., Yan, Y., & Huang, W. (2020) · Translational Neuroscience · doi:10.1515/tnsci-2020-0101 · Cited by 23
Retracted
Metadata
- Authors
- Liu, X., Jiao, B., & Shen, L.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2018-11-30
- Volume
- 9
- Pages
- 579-579
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2902243754
- Cited by
- 144
- References
- 38
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.